MEDIA

Media Inquiries

Gem Hopkins

Video Feed

3D MOA Animation video

OncoSec's VLA 3D MOA Animation

TAVO Demonstration with Dr Algazi

OncoSec at 2020 BIO CEO Panel

Tumor Immunogenicity

IAD Reel

IAD Robert Andtbacka, M.D.

Social Media

Twitter Feed

.@ad1600 of @UCSFCancer explains our KEYNOTE-695 #clinicaltrial, using our investigational product #TAVOᵀᴹ in combination with #KEYTRUDA® to potentially treat #melanoma. Listen to Dr. Daud's full description here: https://event.on24.com/wcc/r/2345516/B6AD55C4589FCE8B2787793FB5319FF6 #TogetherAgainstCancer

After 2 decades working in the CRO industry, our Chief Clinical Development Officer, Kellie Malloy Foerter, is applying her expertise to guide our clinical development programs for #cancer with limited treatment options. Learn more: https://www.pharmavoice.com/wow-podcasts/wow-kellie-malloy-foerter/ #TogetherAgainstCancer

Recently, @cancerhealthmag explored our data published in @CCR_AACR showing our investigational candidate, #TAVO™, with KEYTRUDA® produced a 41% overall response rate and 36% complete response in late-stage #metastatic #melanoma: https://www.cancerhealth.com/article/interleukin12-electroporation-may-sensitize-cold-melanomas-immune-checkpoint-inhibition
#TogetherAgainstCancer

According to @theNCI, #SkinCancer is the most common #cancer. Visit https://oncosec.com/ to learn more about our commitment to deliver safer and more effective treatments for #metastatic #melanoma and other types of cancer. #TogetherAgainstCancer